Ysios et al. invest €18m in Cellerix

Cellerix's existing backers - including Ysios Capital Partners, Life Science Partners and Ventech - all contributed to the capital increase. The company previously raised €27.2m of early-stage financing in 2007; this second funding round was jointly led by Life Sciences Partners and Ventech.

Following the operation, Cellerix will merge with Belgian biopharma TiGenix by means of a share for share exchange. Including the latest capital increase, the transaction will value Cellerix at around €58m.

Headquartered in Leuven, the combined entity will also have operations in Spain, the Netherlands and the United Kingdom. Specialised in cell therapy, the group will particularly focus on the treatment of damaged and arthritic joints.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain
• Life Science Partners